|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1987-4-13
|
|
pubmed:abstractText |
Epirubicin was studied in a phase I setting to find the maximum tolerated dose when given weekly for 3 of 4 weeks. Forty-one evaluable patients were treated in groups at doses increasing from 20 to 45 mg/m2. The highest dose level produced the maximum degree of myelosuppression (lowest neutrophil count, 1.9 X 10(9)/L; range, 0-3.7) recorded on Day 22. This was well-tolerated in this group of mainly pretreated patients. Nonhematologic side effects were minimal. This dose schedule allows a greater dose per unit time to be administered than other recommended schedules for epirubicin.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0361-5960
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
273-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:3028619-Adult,
pubmed-meshheading:3028619-Aged,
pubmed-meshheading:3028619-Breast Neoplasms,
pubmed-meshheading:3028619-Carcinoma, Small Cell,
pubmed-meshheading:3028619-Doxorubicin,
pubmed-meshheading:3028619-Drug Administration Schedule,
pubmed-meshheading:3028619-Drug Evaluation,
pubmed-meshheading:3028619-Epirubicin,
pubmed-meshheading:3028619-Female,
pubmed-meshheading:3028619-Heart Diseases,
pubmed-meshheading:3028619-Hematologic Diseases,
pubmed-meshheading:3028619-Humans,
pubmed-meshheading:3028619-Lung Neoplasms,
pubmed-meshheading:3028619-Male,
pubmed-meshheading:3028619-Middle Aged
|
|
pubmed:year |
1987
|
|
pubmed:articleTitle |
Phase I study of epirubicin given on a weekly schedule.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
